Navigation Links
SPO Medical to Conduct Live Investor Meeting on April 29, 2008
Date:4/10/2008

ut future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, the introduction of competing products, market acceptance of our new products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007. We undertake no obligation to revise or update any forward-looking statement for any reason.

Investor Contacts

SPO Medical: Target 3 Communications:

Michael Braunold, President & CEO Eugene Feyman, Director

info@spomedical.com eugene@target3.com

+1-805-823-8163 +1-646-827-0009


'/>"/>
SOURCE SPO Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Winston-Salem, NC (PRWEB) November 26, 2014 ... Medical Advisory Board. PMG Research is a network of sites ... with access to over 2 million patient lives through its ... Research is comprised of 11 hub site locations in the ... , The first term of the board will ...
(Date:11/26/2014)... 25, 2014 The Pittcon marketing department ... conference and exposition mobile app, Pittcon ... in the App Store for iOS and Android devices ... tool before, during and after the event. It acts ... exhibiting companies, technical sessions, Conferee Networking sessions and short ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is an in-depth research report on the Global ... report introduces Palmitic Acid, basic information, including definition, ... analysis, and news analysis, etc. , For ... Palmitic Acid market in China and ...
(Date:11/24/2014)... , Nov. 24, 2014  IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... to the U.S. Food and Drug Administration (FDA), which ... 2014 to seven, with eighteen submissions now pending at ... President and CEO of the Company, commented, "Our team ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Pittcon Releases 2015 Mobile App 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3IGI Laboratories, Inc. Announces ANDA Submission 2
... BASKING RIDGE, N.J., Aug. 24 Regado ... of antithrombotic therapeutic aptamers with active control agents, today ... Phase I study of a subcutaneous administration formulation of ... randomized, placebo-controlled, single ascending dose study to evaluate safety, ...
... CAMBRIDGE, Mass., Aug 24 Shire plc (LSE: SHP, NASDAQ: ... today that it has entered into a research-based collaboration with ... develop its proprietary Locked Nucleic Acid (LNA) technology in a ... its already strong competitive position for its Human Genetic Therapies ...
... August 24 , - Santaris ... Research,Program Utilizing Santaris Pharma,s Proprietary Locked Nucleic Acid (LNA),Drug Platform ... Treatment of Rare Genetic Disorders , ... and Royalties for Providing Access to its LNA Technology,Exclusivity for ...
Cached Biology Technology:Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System 2Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform 2Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform 4Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders 2Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders 3Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders 4
(Date:11/4/2014)... marketing directed at children on the interior and ... the majority of black, middle-income and rural communities ... Authored by Arizona State University researcher Punam Ohri-Vachaspati ... to examine the use of child-directed marketing on ... and its relationship to demographics. It adds to ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... ANGELES , Nov. 3, 2014  NeuroSigma ... -based life sciences company focused on commercialization ... system for the treatment of neurological and ... of Industrial Property has issued a Notice of ... patent application is co-owned by NeuroSigma and the ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... The Gerontological Society of America (GSA) the ... has chosen Pankaj Kapahi, PhD, of the Buck Institute ... Shock New Investigator Award. The distinguished honor is given ... biological research. It was established in 1986 to honor Nathan ...
... An NPL imaging scientist Agnieszka Bialek won the Royal ... spectral imaging. The Selwyn Award is sponsored by ... introduced in 1994 in memory of E W H Selwyn, ... to a scientist under the age of 35 who has ...
... descendents of the first plants that colonized land and ... invasive pests and habitat loss, especially those species endemic ... published recently as the cover article in ... these plants as relicts (leftovers of formerly abundant organisms), ...
Cached Biology News:National Physical Laboratory scientist wins photographic award 2New research on rapidly disappearing ancient plant offers hope for species recovery 2New research on rapidly disappearing ancient plant offers hope for species recovery 3
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
... antibody raised against a partial recombinant IFNA2. ... partial recombinant protein is produced in E. coli. ... IU/ mg. OMIM: 147562, ... Lot Number: MM951100564 MA Code: ...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Biology Products: